Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price
The average list price of $96,000 per year is three times the cost of GW’s competing drug Epidiolex, but Zogenix is betting that the reduction in seizures seen in clinical trials will justify the expense.
